Allianz Asset Management GmbH bought a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 68,880 shares of the company’s stock, valued at approximately $3,465,000. Allianz Asset Management GmbH owned 0.06% of Ionis Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in IONS. Ark Investment Management LLC raised its holdings in shares of Ionis Pharmaceuticals by 38.7% during the second quarter. Ark Investment Management LLC now owns 176,991 shares of the company’s stock valued at $9,004,000 after purchasing an additional 49,428 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Ionis Pharmaceuticals by 9.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. Crossmark Global Holdings Inc. acquired a new position in shares of Ionis Pharmaceuticals during the third quarter valued at about $254,000. Swiss National Bank raised its holdings in shares of Ionis Pharmaceuticals by 2.7% during the third quarter. Swiss National Bank now owns 207,300 shares of the company’s stock valued at $10,510,000 after purchasing an additional 5,400 shares during the period. Finally, Sei Investments Co. raised its holdings in shares of Ionis Pharmaceuticals by 8.7% during the third quarter. Sei Investments Co. now owns 55,849 shares of the company’s stock valued at $2,832,000 after purchasing an additional 4,492 shares during the period. Institutional investors and hedge funds own 90.71% of the company’s stock.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total value of $1,100,220.00. Following the completion of the sale, the chairman now directly owns 58,014 shares of the company’s stock, valued at approximately $2,901,280.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph Klein III sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $51.13, for a total transaction of $102,260.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,635 shares of company stock valued at $5,615,581. 2.13% of the stock is currently owned by insiders.
Shares of Ionis Pharmaceuticals Inc (IONS) opened at $52.61 on Tuesday. The company has a current ratio of 5.20, a quick ratio of 5.15 and a debt-to-equity ratio of 1.45. The company has a market cap of $6,482.09, a PE ratio of -1,314.92 and a beta of 2.44. Ionis Pharmaceuticals Inc has a 52-week low of $37.26 and a 52-week high of $65.51.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.10. The company had revenue of $172.00 million during the quarter, compared to the consensus estimate of $126.38 million. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 earnings per share. research analysts anticipate that Ionis Pharmaceuticals Inc will post -0.33 EPS for the current year.
IONS has been the topic of several research reports. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 10th. Sanford C. Bernstein reiterated a “market perform” rating and set a $55.00 price objective (down previously from $61.00) on shares of Ionis Pharmaceuticals in a report on Tuesday, February 20th. Stifel Nicolaus upped their price objective on shares of Ionis Pharmaceuticals from $55.00 to $57.00 and gave the company a “hold” rating in a report on Wednesday, February 28th. Finally, TheStreet lowered shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $51.12.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.